IP Library › Granted Patent US 12,516,065
Granted Patent B2
US 12,516,065 · App. 18/430,528 · Granted Jan 6, 2026

Tertiary alcohols as PI3K-γ inhibitors

Inventors: Brent Douty (Fallowfield, PA); Andrew W. Buesking (Wilmington, DE); David M. Burns (Plymouth Meeting, PA); Andrew P. Combs (Kennett Square, PA); Nikoo Falahatpisheh (Wilmington, DE); Ravi Kumar Jalluri (Avondale, PA); Daniel Levy (Philadelphia, PA); Padmaja Polam (Kennett Square, PA); Lixin Shao (Wilmington, DE); Stacey Shepard (Wilmington, DE); Artem Shvartsbart (Kennett Square, PA); Richard B. Sparks (Hockessin, DE); Eddy W. Yue (Landenberg, PA)
Assignee: Incyte Corporation
C07D487/04A61P25/28A61P35/00C07B2200/07C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,516,065
App. No.
18/430,528
Granted
Jan 6, 2026
Kind
B2
Abstract

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Claims (14)

1 . A method of treating a disease or disorder in a patient, wherein said disease or disorder is associated with abnormal expression or activity of PI3Kγ kinase and is selected from the group consisting of tumors, sarcomas, lymphomas, leukemias, autoimmune diseases or disorders, inflammatory diseases or disorders, and cancers, the method comprising administering to said patient a therapeutically effective amount of 2-(3-(8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the disease or disorder is Burkitt's lymphoma, acute myeloblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, Mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, xeroderma pigmentosum, keratoacanthoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, mucosa-associated lymphatic tissue (MALT) lymphoma, mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smoldering myeloma (aka asymptomatic myeloma), monoclonal gammopathy of undetermined significance (MGUS), or diffuse large B cell lymphoma.

3 . The method of claim 2 , wherein the disease or disorder is non-Hodgkin's lymphoma (NHL) selected from relapsed NHL, refractory NHL, recurrent follicular NHL, indolent NHL (iNHL), and aggressive NHL (aNHL).

4 . The method of claim 2 , wherein the disease or disorder is diffuse large B cell lymphoma selected from activated B-cell like (ABC) diffuse large B cell lymphoma and germinal center B cell (GCB) diffuse large B cell lymphoma.

5 . The method of claim 1 , wherein the disease or disorder is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, asthma, allergy, allergic rhinitis, pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease, thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hypertrophy, myasthenia gravis, Sjögren's syndrome, osteoarthritis, restenosis, or atherosclerosis.

6 . The method of claim 1 , wherein the disease or disorder is heart hypertrophy, cardiac myocyte dysfunction, acute coronary syndrome, chronic obstructive pulmonary disease (COPD), chronic bronchitis, elevated blood pressure, ischemia, ischemia-reperfusion, vasoconstriction, anemia, bacterial infection, viral infection, graft rejection, kidney disease, anaphylactic shock fibrosis, skeletal muscle atrophy, skeletal muscle hypertrophy, angiogenesis, sepsis, graft-versus-host disease, allogeneic or xenogeneic transplantation, glomerulosclerosis, progressive renal fibrosis, idiopathic thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, or membranous nephropathy.

7 . The method of claim 1 , wherein the disease or disorder is Mantle cell lymphoma.

8 . The method of claim 1 , wherein the disease or disorder is follicular lymphoma.

9 . The method of claim 1 , wherein the disease or disorder is extranodal marginal zone lymphoma.

10 . The method of claim 1 , wherein the disease or disorder is myelofibrosis.

11 . The method of claim 1 , wherein the disease or disorder is splenic marginal zone lymphoma.

12 . The method of claim 1 , wherein the disease or disorder is diffuse large B cell lymphoma.

13 . The method of claim 1 , wherein the disease or disorder is Sjögren's syndrome.

14 . The method of claim 1 , wherein the disease or disorder is autoimmune hemolytic anemia.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2024
From: DOUTY, BRENT; BUESKING, ANDREW W.; BURNS, DAVID M.; COMBS, ANDREW P.; FALAHATPISHEH, NIKOO; JALLURI, RAVI KUMAR; LEVY, DANIEL; POLAM, PADMAJA; SHAO, LIXIN; SHEPARD, STACEY; SHVARTSBART, ARTEM; SPARKS, RICHARD B.; YUE, EDDY W.
To: INCYTE CORPORATION
Reel/Frame 066469/0393 →
Continuity (7)
Continuation 17537674 · Nov 30, 2021
Continuation 16913488 · Jun 26, 2020
Division 16163341 · Oct 17, 2018
Provisional Application 62727316 · Sep 5, 2018
Provisional Application 62608897 · Dec 21, 2017
Provisional Application 62574057 · Oct 18, 2017
Related Publication 20240228498A1 · Jul 11, 2024
References Cited (270)
US 4269846A · Huang et al. · 1981 [cited by applicant]
US 5137876A · MacCoss et al. · 1992 [cited by applicant]
US 5521184A · Zimmermann · 1996 [cited by applicant]
US 7186832B2 · Sun · 2007 [cited by applicant]
US 7511145B2 · Schmitz et al. · 2009 [cited by applicant]
US 8329697B2 · Garbaccio et al. · 2012 [cited by applicant]
US 8680108B2 · Li et al. · 2014 [cited by applicant]
US 8759359B2 · Combs et al. · 2014 [cited by applicant]
US 8940752B2 · Li et al. · 2015 [cited by applicant]
US 9062055B2 · Li et al. · 2015 [cited by applicant]
US 9096600B2 · Li et al. · 2015 [cited by applicant]
US 9108984B2 · Combs et al. · 2015 [cited by applicant]
US 9126948B2 · Combs et al. · 2015 [cited by applicant]
US 9193721B2 · Combs et al. · 2015 [cited by applicant]
US 9199982B2 · Li et al. · 2015 [cited by applicant]
US 9586949B2 · Zou et al. · 2017 [cited by applicant]
US 10022387B2 · Zou et al. · 2018 [cited by applicant]
US 10065963B2 · Shvartsbart et al. · 2018 [cited by applicant]
US 10138248B2 · Buesking et al. · 2018 [cited by applicant]
US 10472368B2 · Shvartsbart et al. · 2019 [cited by applicant]
US 10479795B2 · Buesking et al. · 2019 [cited by applicant]
US 10738057B2 · Douty et al. · 2020 [cited by applicant]
US 11186580B2 · Douty et al. · 2021 [cited by applicant]
US 11225486B2 · Douty · 2022 [cited by examiner]
US 11926630B2 · Douty et al. · 2024 [cited by applicant]
US 12173006B2 · Douty et al. · 2024 [cited by applicant]
US 20040220189A1 · Sun et al. · 2004 [cited by applicant]
US 20050009832A1 · Sun et al. · 2005 [cited by applicant]
US 20070099925A1 · Calderwood et al. · 2007 [cited by applicant]
US 20070225286A1 · Ren et al. · 2007 [cited by applicant]
US 20100298334A1 · Rodgers et al. · 2010 [cited by applicant]
US 20110015212A1 · Li et al. · 2011 [cited by applicant]
US 20110059951A1 · Rodgers et al. · 2011 [cited by applicant]
US 20110224190A1 · Huang et al. · 2011 [cited by applicant]
US 20120149681A1 · Rodgers et al. · 2012 [cited by applicant]
US 20120149682A1 · Rodgers et al. · 2012 [cited by applicant]
US 20120157430A1 · Li et al. · 2012 [cited by applicant]
US 20120238564A1 · Luk et al. · 2012 [cited by applicant]
US 20120329792A1 · Bartolome-Nebreda et al. · 2012 [cited by applicant]
US 20130018034A1 · Yao et al. · 2013 [cited by applicant]
US 20130045963A1 · Rodgers et al. · 2013 [cited by applicant]
US 20130059835A1 · Li et al. · 2013 [cited by applicant]
US 20130261101A1 · Combs et al. · 2013 [cited by applicant]
US 20140005166A1 · Rodgers et al. · 2014 [cited by applicant]
US 20140121198A1 · Li et al. · 2014 [cited by applicant]
US 20140249132A1 · Li et al. · 2014 [cited by applicant]
US 20140275127A1 · Combs et al. · 2014 [cited by applicant]
US 20140343030A1 · Li et al. · 2014 [cited by applicant]
US 20150005309A1 · Barfacker et al. · 2015 [cited by applicant]
US 20150284390A1 · Li et al. · 2015 [cited by applicant]
US 20150361094A1 · Li et al. · 2015 [cited by applicant]
US 20160000795A1 · Scherle et al. · 2016 [cited by applicant]
US 20160022685A1 · Li et al. · 2016 [cited by applicant]
US 20160024117A1 · Li et al. · 2016 [cited by applicant]
US 20170129899A1 · Shvartsbart et al. · 2017 [cited by applicant]
US 20170190689A1 · Sparks et al. · 2017 [cited by applicant]
US 20180009816A1 · Buesking et al. · 2018 [cited by applicant]
US 20180057469A1 · Wu et al. · 2018 [cited by applicant]
US 20190060331A1 · Zou et al. · 2019 [cited by applicant]
US 20190062336A1 · Shvartsbart et al. · 2019 [cited by applicant]
US 20190119287A1 · Buesking et al. · 2019 [cited by applicant]
US 20190152975A1 · Douty et al. · 2019 [cited by applicant]
US 20190359592A1 · Sparks et al. · 2019 [cited by applicant]
US 20200071335A1 · Douty et al. · 2020 [cited by applicant]
US 20200385392A1 · Douty et al. · 2020 [cited by applicant]
US 20220112198A1 · Douty et al. · 2022 [cited by applicant]
US 20220213107A1 · Douty et al. · 2022 [cited by applicant]
US 20250243206A1 · Douty et al. · 2025 [cited by applicant]
CL 201202487 · 2012 [cited by applicant]
CL 201502442 · 2016 [cited by applicant]
CL 201902324 · 2019 [cited by applicant]
CL 202000215 · 2020 [cited by applicant]
CL 202001047 · 2020 [cited by applicant]
CL 202001680 · 2020 [cited by applicant]
CL 202000664 · 2020 [cited by applicant]
CL 202001501 · 2020 [cited by applicant]
CL 202001632 · 2020 [cited by applicant]
CL 202001009 · 2020 [cited by applicant]
CN 1898240 · 2007 [cited by applicant]
CN 102428087 · 2012 [cited by applicant]
EP 2044051 · 2010 [cited by applicant]
JP 2015503601 · 2015 [cited by applicant]
WO WO2000009495 · 2000 [cited by applicant]
WO WO2000053595 · 2000 [cited by applicant]
WO WO2001014402 · 2001 [cited by applicant]
WO WO2001064655 · 2001 [cited by applicant]
WO WO2001085724 · 2001 [cited by applicant]
WO WO2002000196 · 2002 [cited by applicant]
WO WO2003024967 · 2003 [cited by applicant]
WO WO2003035065 · 2003 [cited by applicant]
WO WO2003035644 · 2003 [cited by applicant]
WO WO2003037347 · 2003 [cited by applicant]
WO WO2003068225 · 2003 [cited by applicant]
WO WO2003099771 · 2003 [cited by applicant]
WO WO2004005281 · 2004 [cited by applicant]
WO WO2004046120 · 2004 [cited by applicant]
WO WO2004056786 · 2004 [cited by applicant]
WO WO2004078943 · 2004 [cited by applicant]
WO WO2004080980 · 2004 [cited by applicant]
WO WO2005012288 · 2005 [cited by applicant]
WO WO2005028444 · 2005 [cited by applicant]
WO WO2005118580 · 2005 [cited by applicant]
WO WO2006056399 · 2006 [cited by applicant]
WO WO2007019416 · 2007 [cited by applicant]
WO WO2007019417 · 2007 [cited by applicant]
WO WO2007028051 · 2007 [cited by applicant]
WO WO2009005551 · 2009 [cited by applicant]
WO WO2009016118 · 2009 [cited by applicant]
WO WO2009024585 · 2009 [cited by applicant]
WO WO2009064835 · 2009 [cited by applicant]
WO WO2009079011 · 2009 [cited by applicant]
WO WO2009114512 · 2009 [cited by applicant]
WO WO2009123776 · 2009 [cited by applicant]
WO WO2009133127 · 2009 [cited by applicant]
WO WO2009158118 · 2009 [cited by applicant]
WO WO2010051245 · 2010 [cited by applicant]
WO WO2010061903 · 2010 [cited by applicant]
WO WO2010069684 · 2010 [cited by applicant]
WO WO2010135014 · 2010 [cited by applicant]
WO WO2011099832 · 2011 [cited by applicant]
WO WO2011123609 · 2011 [cited by applicant]
WO WO2011149856 · 2011 [cited by applicant]
WO WO2011149874 · 2011 [cited by applicant]
WO WO2012051410 · 2012 [cited by applicant]
WO WO2012074126 · 2012 [cited by applicant]
WO WO2012143796 · 2012 [cited by applicant]
WO WO2012170867 · 2012 [cited by applicant]
WO WO2013104610 · 2013 [cited by applicant]
WO WO2013129674 · 2013 [cited by applicant]
WO WO2013180193 · 2013 [cited by applicant]
WO WO2014009295 · 2014 [cited by applicant]
WO WO2014011900 · 2014 [cited by applicant]
WO WO2014149207 · 2014 [cited by applicant]
WO WO2014153529 · 2014 [cited by applicant]
WO WO2014182954 · 2014 [cited by applicant]
WO WO2015008872 · 2015 [cited by applicant]
WO WO2015051241 · 2015 [cited by applicant]
WO WO2015154878 · 2015 [cited by applicant]
WO WO2016044342 · 2016 [cited by applicant]
WO WO2016064957 · 2016 [cited by applicant]
WO WO2016064958 · 2016 [cited by applicant]
WO WO2016075130 · 2016 [cited by applicant]
WO WO2016106624 · 2016 [cited by applicant]
WO WO2016166239 · 2016 [cited by applicant]
WO WO2016183094 · 2016 [cited by applicant]
WO WO2017223414 · 2017 [cited by applicant]
WO WO2018038265 · 2018 [cited by applicant]
WO WO2019079469 · 2019 [cited by applicant]
Atzrodt et al., “The Renaissance of H/D Exchange,” Angew Chem Int Ed., Oct. 4, 2007, 46(41): 7744-7765. [cited by applicant]
Australian Office Action in Australian Application No. 2018350980, dated Feb. 16, 2022, 7 pages. [cited by applicant]
Bala et al., “Highly efficient water-mediated approach to access benzazoles: metal catalyst and base-free synthesis of 2-substituted benzimidazoles, benzoxazoles, and benzothiazoles,” Molecular Diversity, Mar. 2015, 19(… [cited by applicant]
Barber et al., “PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus,” Nat Medicine, Sep. 2005, 11(9):933-935. [cited by applicant]
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 1977, 66(2):1-19. [cited by applicant]
Berod et al., “PI3Kγ deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome,” Euro J Immunol., Mar. 2011, 41(3):833-844. [cited by applicant]
Blom et al., “Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification,” J Comb Chem., 2003, 5(5):670-683. [cited by applicant]
Blom et al., “Preparative LC-MS Purification: Improved Compound Specific Method Optimization,” J Comb Chem., 2004, 6(6):874-883. [cited by applicant]
Blom et al., “Two-Pump at Column Dilution Configuration for Preparative LC-MS,” J Comb. Chem., Jul.-Aug. 2002, 4(295):295-301. [cited by applicant]
Brock et al., “Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma,” J Biol Chem., Jan. 6, 2003, 160(1):89-99. [cited by applicant]
Bruneau et al., “2-Aminobiphenyl Palladacycles: The “Most Powerful” Precatalysts in C—C and C-Heteroatom Cross-Couplings,” ACS Catal., 2015, 5(2):1386-1396. [cited by applicant]
Buesking et al., “Asymmetric Synthesis of Protected α-Amino Boronic Acid Derivatives with an Air- and Moisture-Stable Cu(II) Catalyst,” J Org Chem., Mar. 31, 2014, 79(8):3671-3677. [cited by applicant]
Camps et al., “Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis,” Nat Medicine, 2005, 11(9):939-943. [cited by applicant]
Cantley, “The phosphoinositide 3-kinase pathway,” Science, May 31, 2002, 296(5573):1655-1657. [cited by applicant]
Carter et al., “Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM),” Cancer Biol Ther., Sep. 15, 2010, 10(6):582-587. [cited by applicant]
Chilean Office Action in Chilean Application No. 1047-2020, dated Apr. 9, 2021, 19 pages. [cited by applicant]
Chilean Office Action in Chilean Application No. 202100539, dated May 13, 2022, 24 pages. [cited by applicant]
Chilean Office Action in Chilean Application No. 202100539, dated Nov. 18, 2022, 36 pages (with machine translation). [cited by applicant]
Chinese Office Action in Chinese Application No. 201880081276.3, dated Sep. 19, 2022, 17 pages. [cited by applicant]
Choudhury-Mukherjee et al., “Design, synthesis, and evaluation of analogues of 3,3,3-trifluoro-2-hydroxy-2-phenyl-propionamide as orally available general anesthetics,” J Med Chem, Jun. 5, 2003, 46(12):2494-2501. [cited by applicant]
Collier et al., “Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ,” Journal of Medicinal Chemistry, Jul. 26, 2015, 58: 5684-5688. [cited by applicant]
Collier et al., “Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase [gamma],” Journal of Medicinal Chemistry, Jan. 2015, 58(1): 517-521. [cited by applicant]
Comerford et al., “PI3Kγ Drives Priming and Survival of Autoreactive CD4+ T Cells during Experimental Autoimmune Encephalomyelitis,” PLOS one, Sep. 2012, 7(9):e45095. [cited by applicant]
Cossy et al., “Formation of optically active 3-hydroxypiperidines,” Tetrahedron Letters, Jan. 23, 1995, 36(4):549-552. [cited by applicant]
Cushing et al., “PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases,” Journal of Medicinal Chemistry, Sep. 13, 2012, 55: 8559-8581. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US, Jun. 1, 2015, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755361, Database Accession No. 1770353-29-1. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US, Jun. 4, 2015, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755362, Database Accession No. 1773443-64-3. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US, May 29, 2015, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755360, Database Accession No. 1715195-44-0. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Aug. 2012, CAS client services: XP002755356, Database accession No. 1391828-67-3. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Dec. 2011, Chemical Catalog; Supplier: Ukrorgsyntez ltd.: XP002755357, Database accession No. 1347088-14-5. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Dec. 2012, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755355, Database accession No. 1411464-90-8. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Feb. 2014, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755346, Database accession No. 1554931-95-1. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Feb. 2014, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755347, Database accession No. 1540856-06-1. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Feb. 2014, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755349, Database accession No. 1538237-68-1. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Feb. 2014, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755350, Database accession No. 1536955-67-5. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Jan. 2014, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755351, Database accession No. 1528719-88-1. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Jan. 2014, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755352, Database accession No. 1526778-80-2. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Jan. 2014, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755353, Database accession No. 1522493-70-4. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Jan. 2014, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755354, Database accession No. 1520181-20-7. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Oct. 2005, Chemical Library; Supplier: interchim: XP002755358, Database accession No. 866138-38-7. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, OH, US; Oct. 2005, Chemical Library; Supplier: interchim: XP002755359, Database accession No. 864939-76-4. [cited by applicant]
Database Registry [online], Chemical Abstracts Service, Columbus, Ohio, US, Feb. 2010, Chemical Catalog; Supplier: Aurora Fine Chemicals: XP002755348, Database accession No. 1540777-22-7. [cited by applicant]
Doukas et al., “Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary dise… [cited by applicant]
Doukas et al., “Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury,” Proc Natl Acad Sci USA., Dec. 26, 2006, 103(52):19866-19871. [cited by applicant]
Ecuador Opposition in Ecuador Application No. SENADI-2021-22719, dated Jun. 2022, 20 pages. [cited by applicant]
El Khoury et al., “Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease,” Nat Med, 2007, 13(4):432-438. [cited by applicant]
Elger et al., “Novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodege… [cited by applicant]
Eurasian Office Action in Eurasian Application No. 202090969, dated Nov. 18, 2021, 4 pages. [cited by applicant]
Eurasian Office Action in Eurasian Application No. 202190679, dated Dec. 22, 2022, 2 pages. [cited by applicant]
European Search Report in European Application No. 19858443.5, dated Apr. 13, 2022, 12 pages. [cited by applicant]
European Search Report in European Application No. 21196484.6, dated Apr. 8, 2022, 8 pages. [cited by applicant]
Falasca and Mufficci, “Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts,” Frontiers in Physiology, Oct. 15, 2014, 5:1-10. [cited by applicant]
Garamvolgyi et al., “Design and Synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivates with antiproliferative activity against melanoma cells,” Eur J Med Chem., Jan. 27, 2018, 108:623-643. [cited by applicant]
Georgian office action in Georgian application No. 15327, dated May 23, 2022, 6 pages. [cited by applicant]
Giri et al., “Mechanism of amyloid peptide induced CCR5 expression in monocytes and its inhibition by siRNA for Egr-1,” Am J Physiol Cell Physiol., Aug. 2005, 289:C264-C276. [cited by applicant]
Giron, “Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates,” Thermochimica Acta., 1995, 1-59 pages. [cited by applicant]
Gonzalez-Garcia et al., “Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer,” Gastroenterology, Apr. 2010, 138(4):1373-1384. [cited by applicant]
Gupta et al., “Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations,” Molecules, Jul. 14, 2018, 23(7):1719, 15 pages. [cited by applicant]
Hannahan and Weinberg, “Hallmarks of cancer: the next generation,” Cell, Mar. 4, 2011, 144(5):646-674. [cited by applicant]
Hayer et al., “PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis,” FASB J, 2009, 23(12):4288-4298. [cited by applicant]
Indian Office Action in Indian Application No. 202017018665, dated Oct. 12, 2021, 5 pages. [cited by applicant]
Indian Office Action in Indian Application No. 202117012127 dated Sep. 8, 2022, 6 pages. [cited by applicant]
Indonesian Office Action in Indonesian Application No. P00202003332, dated Dec. 2, 2021, 8 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2016/017073, dated Aug. 15, 2017, 11 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2016/060468, dated May 8, 2018, 9 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2017/012135, dated Jul. 19, 2018, 10 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2017/038955, dated Dec. 25, 2018, 8 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/056311, mailed Apr. 30, 2020, 8 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2019/049419, mailed Mar. 18, 2021, 7 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/017073, dated Apr. 15, 2016, 21 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/060468, dated Jan. 25, 2017, 11 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2017/012135, dated May 19, 2017, 17 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2017/038955, dated Aug. 8, 2017, 15 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2018/056311, dated Jan. 21, 2019, 10 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2019/49419, dated Jan. 31, 2020, 10 pages. [cited by applicant]
Invitation to Pay Additional Fees in International Application No. PCT/US19/49419, dated Dec. 5, 2019, 10 pages. [cited by applicant]
Israeli Office Action in Israeli Application No. 273983, dated Mar. 28, 2022, 3 pages. [cited by applicant]
Japanese Office Action in Japanese Application No. 2020-521911, dated Sep. 16, 2022, 4 pages. [cited by applicant]
Jimenez et al., “The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras,” J Biol Chem., Nov. 1, 2002, 277(44):41556-415562. [cited by applicant]
Kaneda et al., “Abstract 3650: PI3-kinase gamma controls the macrophage M1-M2 switch, thereby promoting tumor immunosuppression and progression,” Presented at the Proceedings of the AACR Annual Meeting 2014, San Diego, … [cited by applicant]
Kendell et al., “Bromopropionic Acid,” Organic Synthesis, 1941, 1:131. [cited by applicant]
Kerekes et al., “Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure,” J Med Chem., Jan. 13, 2011, 54(1):201-210. [cited by applicant]
Kolb et al., “Catalytic Asymmetric Dihydroxylation,” Chem Rev., 1994, 94(8):2483-2547. [cited by applicant]
Kumar et al., “Discovery and optimization of a new class of pyruvate kinase inhibitors as potential therapeutics for the treatment of methicillin-resistant [cited by applicant]
Laffargue et al., “Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function,” Immunity, 2002, 16(3):441-451. [cited by applicant]
Li et al., “PI3Kγ inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice,” Neuroscience, 2013, 253:89-99. [cited by applicant]
Liu et al., “Advances in Synthesis and Application of Imidazopyridine Derivatives,” Progress in Chemistry, Apr. 30, 2010, 22(4):631-638 (with English abstract). [cited by applicant]
Liu et al., “Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia,” ACS Med. Chem. Lett., Feb. 9, 2012, 3(2):129-134. [cited by applicant]
Lupia et al., “Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis,” Am J Pathology., Dec. 2004, 165(6):2003-2011. [cited by applicant]
Mamedov et al., “Acid-catalyzed rearrangement of 3-(beta-2-aminostyryl)quinoxalin-2(1H)ones—a new and efficient method for the synthesis of 2-benzimidazol-2-ylquinolines,” Tetrahedron Letters, Dec. 2010, 51(50): 6503-65… [cited by applicant]
Manning et al., “An innovative and efficient synthesis of stable isotope labelled 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole via [13C42H3] N-methylpyrazole,” J Label Compd Radiopharm., Nov. 201… [cited by applicant]
Martin et al., “PI3Kγ mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis,” Cancer Cell, 2011, 19(6):805-813. [cited by applicant]
Marvel et al., “Glutaric Acid,” Organic Synthesis, 1941, 1:289. [cited by applicant]
Mejdrova et al., “Highly selective Phosphatidylinositol 4-Kinase III[beta] Inhibitors and Structural Insight into Their Mode of Action,” Journal of Medicinal Chemistry, May 2015, 58(9): 3767-3793. [cited by applicant]
Moreno-Dorado et al., “Enantioselective synthesis of arylmethoxyacetic acid derivatives,” Tetrahedron: Asymmetry, Feb. 21, 2003, 14(4):503-510. [cited by applicant]
Office Action in Chinese Appln. No. 201880081276.3, mailed Apr. 27, 2023, 12 pages (with English Translation). [cited by applicant]
Office Action in Mexican Appln. No. MX/a/2021/002551, mailed Apr. 24, 2023, 8 pages (with Machine Translation). [cited by applicant]
Park et al., “Homogenous proximity tyrosine kinase assays: scintillation proximity assay versus homogenous time-resolved fluorescence,” Anal. Biochem., Apr. 1999, 269(1): 94-104. [cited by applicant]
Passos et al., “Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice,” Brain Behav Immun, Mar. 2010, 24(3):493-501. [cited by applicant]
Pinho et al., “Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation,” L Leukocyte Biology., May 2005, 77(5):800-810. [cited by applicant]
Pomel et al., “Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma,” J. Med. Chem., Jun. 2006, 49(13):3857-71. [cited by applicant]
Prete et al., “Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice,” The EMBO Journal, Sep. 1, 2004, 23(17):3505-3515. [cited by applicant]
Randis et al., “Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils,” Eur J Immunol., May 2008, 38(5):1215-1224. [cited by applicant]
Read, “Hydroxypropionic Acid,” Organic Synthesis, 1941, 1:321. [cited by applicant]
Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, 1985, 17th ed., p. 1418. [cited by applicant]
Remington's Pharmaceutical Sciences. 16th. Mack Pub. Co. Pennsylvania. 1980. pp. 180-181. [cited by applicant]
Rodrigues et al., “Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis,” J Neuroimmunol, May 2010, 222(1-2):90-94. [cited by applicant]
Ruckle et al., “PI3Kgamma inhibition: towards an ‘aspirin of the 21st century’?” Nat Rev Drug Discov., Nov. 2006, 5(11):903-918. [cited by applicant]
Ruiz-Castillo et al., “Applications of Palladium-Catalyzed C—N Cross-Coupling Reactions,” Chem Rev., Oct. 12, 2016, 116(19):12564-12649. [cited by applicant]
Schmid et al., “Receptor tyrosine kinases and TLR/ILIRs unexpectedly activate myeloid cell PI3kγ , a single convergent point promoting tumor inflammation and progression,” Cancer Cell, 2011, 19:715-727. [cited by applicant]
Schmidt et al., “Abstract 411: PI3 Kinase gamma Control of Arginase-1 expression promotes tumor immunosuppression,” Cancer Res., Apr. 15, 2012, 72(Suppl 1). [cited by applicant]
Sharpless et al., “The osmium-catalyzed asymmetric dihydroxylation: a new ligand class and a process improvement,” J Org. Chem., 1992, 57(10):2768-2771. [cited by applicant]
Subramaniam et al., “Targeting nonclassical oncogenes for therapy in T-ALL,” Cancer Cell, 2012, 21(4):459-472. [cited by applicant]
Taiwanese Office Action in Taiwanese Application No. 107136622, dated Oct. 24, 2022, 9 pages. [cited by applicant]
Thomas et al., “Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases,” Eur J Immunol., Apr. 2005, 35(4):1283-1291. [cited by applicant]
Vaillard et al., “Synthesis of 6-substituted 2-pyrrolyl and Indolyl Benzoxazoles by Intramolecular O-Arylation in Photostimulated Reactions,” The Journal of Organic Chemistry, Feb. 2012, 77(3): 1507-1519. [cited by applicant]
Vanhaesebroeck et al., “Signalling by PI3K isoforms: insights from gene-targeted mice,” Trends Biochem Sci, Apr. 2005, 30(4):194-204. [cited by applicant]
Vecchione et al., “Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma,” J Exp Med., 2005, 201:1217-1228. [cited by applicant]
Venable et al., “Phosphoinositide 3-Kinase Gamma (PI3K[gamma]) Inhibitors for the Treatment of Inflammation and Autoimmune Disease,” Recent Patents on Inflammation & Allergy Drug Discovery, Jan. 2010, 4(1): 1-15. [cited by applicant]
Ward et al., “Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors,” Chemistry & Biology, Mar. 2003, 10:207-213. [cited by applicant]
Winterfeldt “Applications of Diisobutylaluminium Hydride (DIBAH) and Triisobutylaluminium (TIBA) as Reducing Agents in Organic Synthesis,” Synthesis 1975, 10:617-630. [cited by applicant]
Xu et al., “Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties,” J Label Compd Radiopharma., Jun. 15, 2015, 58(7):308-312. [cited by applicant]